Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0406810 (
NAME
)
13,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pituitary adenomas can occur in a familial context, or they can be isolated cases, sometimes due to a predisposing syndrome. In multiple endocrine neoplasia type 1, they often associate with a mutation of the menin gene, a tumor-suppressing gene. A new germinal mutation predisposing to the development of multiple endocrine neoplasias has recently been identified in MENI-negative subjects on the gene
CDKN1B
encoding for p27(kip1)protein.
Carney Complex
syndrome--a rare disease--is in more than 60% of the cases linked to the inactivation mutation of a gene located on 17q22-24 that encodes the regulatory subunit 1 of protein kinase A, PRKARIA. Isolated familial pituitary adenomas represent 1.9 to 3.2% of the population of subjects presenting a pituitary adenoma. Low penetrance non-sense mutations, Q14X, IVS3-IG>A and R304X, in 11q12-11q13 region encoding AIP protein, (Aryl hydrocarbon receptor Interacting Protein), have been described by Vierimaa et al, in Finish patients with pituitary adenoma predispositions.
...
PMID:[Familial pituitary adenomas: clinical and genetic aspects]. 1796 54
Introduction
: This review explores insights provided by next-generation sequencing (NGS) of pituitary tumors and the clinical implications.
Areas covered
: Although syndromic forms account for just 5% of pituitary tumours, past Sanger sequencing studies pragmatically focused on them. These studies identified mutations in
MEN1,
CDKN1B
, PRKAR1A, GNAS
and
SDHx
causing Multiple Endocrine Neoplasia-1 (MEN1), MEN4,
Carney Complex
-1, McCune Albright Syndrome and 3P association syndromes, respectively. Furthermore, linkage analysis of single-nucleotide polymorphisms identified
AIP
mutations in 20% with familial isolated pituitary adenomas (FIPA). NGS has enabled further investigation of sporadic tumours. Thus, mutations of
USP8
and
CABLES1
were identified in corticotrophinomas,
BRAF
in papillary craniopharyngiomas and
CTNNB1
in adamantinomatous craniopharyngiomas. NGS also revealed that pituitary tumours occur in the DICER1 syndrome, due to
DICER1
mutations, and
CDH23
mutations occur in FIPA. These discoveries revealed novel therapeutic targets and studies are underway of
BRAF
inhibitors for papillary craniopharyngiomas, and EGFR and USP8 inhibitors for corticotrophinomas.
Expert opinion
: It has become apparent that single-nucleotide variants and small insertion/deletion DNA mutations cannot explain all pituitary tumorigenesis. Integrated and improved analyses including whole-genome sequencing, copy number, and structural variation analyses, RNA sequencing and epigenomic analyses, with improved genomic technologies, are likely to further define the genomic landscape.
...
PMID:Insights into pituitary tumorigenesis: from Sanger sequencing to next-generation sequencing and beyond. 3179 61